ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Cleveland BioLabs, Inc. (“Cleveland BioLabs” or the “Company”) (NASDAQ: CBLI) and/or certain of its officers complied with the federal securities laws in connection with the Company’s public securities offering on January 14, 2014 (the “Offering”). Specifically, the investigation focuses on statements contained in (and incorporated into) the Registration Statement issued in connection with the Offering regarding funding from the Biomedical Advanced Research Development Authority. On January 23, 2014, just days after the Offering, Cleveland BioLabs announced that BARDA “terminated negotiations related to the company's proposal for further development of Entolimod as a medical radiation countermeasure.” The price of CBLI shares fell dramatically on the news.
If you purchased Cleveland BioLabs common stock and warrants pursuant to the Offering and suffered losses on that investment, you are encouraged to contact Holzer & Holzer, LLC and its attorney Marshall P. Dees, Esq. via email at email@example.com, or via toll-free telephone at (888) 508-6832 regarding your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.